Latest study leverages new constructs for nuclear localization signal (NLS) sequences to improve editing efficiency in human immune cells.

The recent wave of layoffs and financial troubles at CRISPR-focused startups should not tarnish the promise of CRISPR.

In the latest market close, CRISPR Therapeutics AG (CRSP) reached $37.77, with a -0.03% movement compared to the previous day. This change lagged the S&P 500's 0.13% gain on the day. On the other hand ...

BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $80 from $86 and keeps a Buy rating on the shares. While Q1 earnings ...

Gene editing and many other useful biotechnology tools came from studies of bacteria fighting off viral invaders. But ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

The Food and Drug Administration has approved the world’s first medicine based on CRISPR gene-editing technology, a ...

Gene editing technologies have cemented their place as a valued method in the biological toolkit used by researchers around the globe.

RAPID-CRISPR test quickly and accurately diagnoses acute promyelocytic leukemia, a rare and aggressive blood cancer, with ...

A longstanding mystery in Parkinson's disease research has been why some individuals carrying pathogenic variants that increase their risk of PD go on to develop the disease, while others who also ...

Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Summit Therapeutics (NASDAQ: SMMT), and Viking Therapeutics (NASDAQ: VKTX) as stocks worth buying now. Prosper Junior Bakiny (CRISPR ...

The once-extinct dire wolf species has been brought back to life after 10,000 years, and George R.R. Martin ‘s “ Game of ...